Liao Xiu-Xiu, Dai Yong-Zhao, Zhao Yao-Zhong, Nie Ke
School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.
Front Pharmacol. 2022 Apr 6;13:855828. doi: 10.3389/fphar.2022.855828. eCollection 2022.
Gasdermin E (GSDME) is a member of the gasdermin protein family, which mediates programmed cell death including apoptosis and pyroptosis. Recently, it was suggested that GSDME is activated by chemotherapeutic drugs to stimulate pyroptosis of cancer cells and trigger anti-tumor immunity, which is identified as a tumor suppressor. However, GSDME-mediated pyroptosis contributes to normal tissue damage, leading to pathological inflammations. Inhibiting GSDME-mediated pyroptosis might be a potential target in ameliorating inflammatory diseases. Therefore, targeting GSDME is a promising option for the treatment of diseases in the future. In this review, we introduce the roles of GSDME-driven programmed cell death in different diseases and the potential targeted therapies of GSDME, so as to provide a foundation for future research.
Gasdermin E(GSDME)是gasdermin蛋白家族的成员,该家族介导包括凋亡和焦亡在内的程序性细胞死亡。最近,有人提出GSDME可被化疗药物激活,以刺激癌细胞焦亡并触发抗肿瘤免疫,GSDME被确定为一种肿瘤抑制因子。然而,GSDME介导的焦亡会导致正常组织损伤,引发病理性炎症。抑制GSDME介导的焦亡可能是改善炎症性疾病的一个潜在靶点。因此,靶向GSDME是未来治疗疾病的一个有前景的选择。在这篇综述中,我们介绍了GSDME驱动的程序性细胞死亡在不同疾病中的作用以及GSDME的潜在靶向治疗方法,以便为未来的研究提供基础。